Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Hemangioblastoma × belzutifan × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1 Endocrine 1 CNS 1

Conditions

von Hippel-Lindau Disease 2 Pheochromocytoma 2 Paraganglioma 2 Carcinoma, Renal Cell 2 Neuroectodermal Tumors, Primitive 1 Neoplasm Metastasis 1 Kidney Neoplasms 1 Hemangioblastoma 1 Glioblastoma 1 Adenoma, Islet Cell 1

Interventions

belzutifan 1 Sunitinib 1 Nivolumab 1 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07167329 2025-09-11

BELIEVE-VHL

AC Camargo Cancer Center

Phase 2 Recruiting

CNSEndocrineGenitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma, Neuroectodermal Tumors, Primitive, Hemangioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡